Log in with your email address username.


[Correspondence] Routine molecular profiling of patients with NSCLC

Fabrice Barlesi and co-workers1 (April 2, p 1415) presented results of the first French nationwide observational study of therapy relevant driver mutations in non-small-cell lung cancer (NSCLC) reflecting routine diagnostic care. This type of study was influenced by diagnostic guidelines of the reimbursement systems, and could not take into account all contingencies (unlike designed clinical trials, in which highly selected patient cohorts encounter restrictive inclusion criteria of a pharmaceutical study protocol).